Impact BioMedical (IBO) Acquires Celios
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality”
February 26, 2025 8:30 AM ESTHOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedicals focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness.
Celios® brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other... More
